Using JAK Inhibitors for Myelofibrosis
"We are thankfully starting to be blessed with more options than weve ever had," but "in the frontline proliferative setting, ruxolitinib has remained the standard of care."
Anthonym Hunter Emory University Drug Administration Society Of Hematologic Oncology Properly Using Hematologic Oncology
Source: medscape.com